PREFERE-Studie im Aufwind

详细信息    查看全文

• 作者：Priv-Doz. Dr. Carsten-H. Ohlmann ; Michael Stöckle ; Peter Albers…
• 关键词：Prostatic neoplasms ; Prostatectomy ; Patient selection ; Image ; guided biopsy ; Radiotherapy ; Brachtherapy
• 刊名：Der Urologe A
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：55
• 期：3
• 页码：313-317
• 全文大小：303 KB
• 参考文献：1.Wiegel T, Stockle M, Bartkowiak D (2015) PREFEREnce-based randomized evaluation of treatment modalities in low or early intermediate-risk prostate cancer. Eur Urol 67:1–2CrossRef PubMed
  2.Baco E, Ukimura O, Rud E et al (2015) Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 67:787–794CrossRef PubMed
  3.Tonttila PP, Lantto J, Paakko E et al (2015) Prebiopsy Multiparametric magnetic resonance imaging for prostate cancer diagnosis in biopsy-naive men with suspected prostate cancer based on elevated prostate-specific antigen values: results from a randomized prospective blinded controlled trial. Eur Urol. doi:10.1016/j.eururo.2015.05.024. (Epub ahead of print)PubMed
  4.Meng X, Rosenkrantz AB, Mendhiratta N et al (2015) Relationship between Prebiopsy Multiparametric magnetic resonance imaging (MRI), biopsy indication, and MRI-ultrasound fusion-targeted prostate biopsy outcomes. Eur Urol. doi:10.1016/j.eururo.2015.06.005. (Epub ahead of print)PubMed
  5.Loch T (2007) Computerized transrectal ultrasound (C-TRUS) of the prostate: detection of cancer in patients with multiple negative systematic random biopsies. World J Urol 25:375–380CrossRef PubMed
  6.Strunk T, Decker G, Willinek W et al (2014) Combination of C‑TRUS with multiparametric MRI: potential for improving detection of prostate cancer. World J Urol 32:335–339CrossRef PubMed
  7.Leitlinienprogramm Onkologie DKG, Deutsche Krebshilfe, AWMF (2014) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms. http://​leitlinienprogra​mm-onkologie.​de/​uploads/​tx_​sbdownloader/​LL_​Prostata_​Langversion_​3.​1.​pdf
  8.Bill-Axelson A, Holmberg L, Garmo H et al (2014) Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 370:932–942CrossRef PubMed PubMedCentral
  9.Bul M, Van Den Bergh RC, Zhu X et al (2012) Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer. Br J Urol Int 110:1672–1677CrossRef
  10.Stattin P, Holmberg E, Johansson JE et al (2010) Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 102:950–958CrossRef PubMed PubMedCentral
  
• 作者单位：Priv-Doz. Dr. Carsten-H. Ohlmann (1)
  Michael Stöckle (1)
  Peter Albers (2)
  Heinz Schmidberger (3)
  Martin Härter (4)
  Glen Kristiansen (5)
  Peter Martus (6)
  Stefan Wellek (7)
  Roswitha Bussar-Maatz (1)
  Thomas Wiegel (8)
  
  1. Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes, Kirrbergerstr., 66421, Homburg/Saar, Deutschland
  2. Klinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
  3. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Mainz, Mainz, Deutschland
  4. Institut und Poliklinik für medizinische Psychologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
  5. Institut für Pathologie, Universitätsklinikum Bonn, Bonn, Deutschland
  6. Institut für Klinische Epidemiologie und Angewandte Biometrie, Universität Tübingen, Tübingen, Deutschland
  7. Institut für Medizinische Biometrie, Epidemiologie und Informatik, Universität Mainz, Mainz, Deutschland
  8. Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Ulm, Deutschland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Urology and Andrology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1433-0563

文摘

The PREFERE study, which compares the treatment options for prostate cancer with low and early intermediate risk, has recorded a noticeable upswing in recruitment since mid-2015. Responsible for this are the revised inclusion criteria and the wide support for this study in Germany. The inclusion criteria opened the study to the use of imaging techniques (MRI, C‑Trus / Anna) and the inclusion of all Gleason 3 + 3 = 6 cancers, regardless of tumor extent. In addition, patients can now be included who, for example due to the size of the prostate or existing obstructive micturition disorders, had a contraindication to percutaneous radiotherapy or brachytherapy – these can now be randomized between active surveillance and radical prostatectomy. With the increased recruitment numbers, it seems realistic that the required milestones in recruiting will be achieved.